Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.46 |
| ▸ | CTSS | P25774 | 13/20 | 0.46 |
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15549462 | 1.00 | CTSK (0.46) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL3263928 | 0.87 | CTSS (0.51) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL16119979 | 0.84 | CTSK (0.45) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL15259348 | 0.81 | CTSK (0.56) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL5958657 | 0.81 | CTSK (0.56) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL18762487 | 0.80 | CTSK (0.48) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL18762484 | 0.80 | CTSK (0.48) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL7854592 | 0.80 | CTSK (0.47) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL2910891 | 0.79 | CTSK (0.58) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL4998308 | 0.79 | CTSK (0.58) | CTSKCTSSCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227314-B2 | Cystathionine-gamma-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227314-B2 | Cystathionine-gamma-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170334866-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334866-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334866-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9771339-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771339-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771339-B2 | Cystathionine-γ-lyase (CSE) inhibitors | SOVA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150175561-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175561-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175561-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| EP-2877175-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | Sova Pharmaceuticals, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014018571-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018569-A1 | CYSTATHIONINE-Y-GAMMA-LYASE (CSE) INHIBITORS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014018571-A2 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175561-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | CTSK 1364/4885CTSS 334/4885CTSL 1648/4885 |
| US-20170334866-A1 | CYSTATHIONINE-GAMMA-LYASE (CSE) INHIBITORS | CBS, CTH, BHMT | CTSK 1364/4885CTSS 334/4885CTSL 1648/4885 |
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | HIF1AN, CBS, COXFA4L2 | CTSK 612/4885CTSS 302/4885CTSL 1340/4885 |
| US-10227314-B2 | Cystathionine-gamma-lyase (CSE) inhibitors | CBS, CTH, BHMT | CTSK 1364/4885CTSS 334/4885CTSL 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.